Are there links between Alzheimer’s disease and ADHD? The efficacy of acetylcholinesterase inhibitors and NMDA receptor antagonists in controlling ADHD symptoms: a systematic review

Are there links between Alzheimer’s disease and ADHD? The efficacy of acetylcholinesterase inhibitors and NMDA receptor antagonists in controlling ADHD symptoms: a systematic review

Abstract Background To assess the effectiveness, safety, and tolerability of anti-Alzheimer agents (memantine, galantamine, rivastigmine, and donepezil) in controlling ADHD symptoms in children, adolescents, and adults. Methods Following the PRISMA guideline, clinical trials assessing the potency of...

Full description

Bibliographic Details
Main Authors:	Ramin Abdi Dezfouli, Sara Akbariforoud, Ensieh Esmaeilidezfouli
Format:	Article
Language:	English
Published:	SpringerOpen 2024-02-01
Series:	Middle East Current Psychiatry
Subjects:	ADHD Alzheimer’s Donepezil Galantamine Memantine Rivastigmine
Online Access:	https://doi.org/10.1186/s43045-024-00405-w

Similar Items

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
by: Débora Nunes, et al.
Published: (2022-10-01)

What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink
by: Venexia M. Walker, et al.
Published: (2018-05-01)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
by: Dan-Dan Li, et al.
Published: (2019-05-01)

The Effects of Donepezil, Galantamine, Rivastigmine and Memantine on Mini-Mental State Examination and Mean Flow Velocity in Patients with Vascular Dementia: A Double-Blinded Randomized Clinical Trial
by: Farhad Iranmanesh, et al.
Published: (2020-03-01)

Safety of Cholinesterase Inhibitors and NMDA Receptors Antagonists for the Treatment of Patients with Dementia
by: A. P. Pereverzev, et al.
Published: (2019-12-01)

Alzheimer's disease - a review of medicinal substances and their derivatives
by: Marika Więcek, et al.
Published: (2024-02-01)

Medicamenteuze behandeling van de ziekte van Alzheimer. De klinische praktijk in Nederland
by: CJM Scho¨lzel-Dorenbos
Published: (2024-01-01)

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model
by: M Bond, et al.
Published: (2012-04-01)

Alzheimer’s disease: clinical management errors
by: V. A. Parfenov
Published: (2020-12-01)

Early diagnosis and treatment of Alzheimer's disease
by: V. A. Parfyonov
Published: (2015-12-01)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
by: Yasir Hasan Siddique, et al.
Published: (2022-01-01)

Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
by: Hossein Pakdaman, et al.
Published: (2015-03-01)

Differential Effects of Acetylcholinesterase Inhibitors on Clinical Responses and Cerebral Blood Flow Changes in Patients with Alzheimer's Disease: A 12-Month, Randomized, and Open-Label Trial
by: Soichiro Shimizu, et al.
Published: (2015-04-01)

Electrocardiographic Effects of Cholinesterase Inhibitors in Patients with Alzheimer’s Disease
by: Ayşe ÇOLAK, et al.
Published: (2022-12-01)

The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study
by: Osman Korucu, et al.
Published: (2018-01-01)

Efficacy and safety of chinese herbal medicines combined with chemical drugs for alzheimer's disease: A systematic review and meta-analysis
by: Li Xu, et al.
Published: (2024-01-01)

A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa® Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil (ROMEO-AD)
by: Hee-Jin Kim, et al.
Published: (2023-05-01)

Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease
by: Federica Prati, et al.
Published: (2016-04-01)

Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs
by: Rona R. Ramsay, et al.
Published: (2017-07-01)

Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis
by: Bo-Ru Jin, et al.
Published: (2019-01-01)

Combined therapy for Alzheimer's disease
by: V. V. Zakharov, et al.
Published: (2022-06-01)

Musical hallucinations treated with acetylcholinesterase inhibitors
by: Jan Dirk eBlom, et al.
Published: (2015-04-01)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
by: Deardorff WJ, et al.
Published: (2016-10-01)

Galantamine of rivastigmine pleister. Een beschrijvend onderzoek op een geheugenpolikliniek in Nederland
by: C.J. Wouters, et al.
Published: (2023-07-01)

Galantamine-memantine combination effective in dementia: Translate to dementia praecox?
by: Maju Mathew Koola, et al.
Published: (2018-06-01)

The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease
by: Shoichi Sasaki, et al.
Published: (2014-05-01)

Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice
by: Constantin Kondak, et al.
Published: (2023-06-01)

Effects of rivastigmine and memantine alone and in combination on learning and memory in rats with scopolamine-induced amnesia
by: Yanev Peter Georgiev, et al.
Published: (2015-09-01)

The impact of fifa on the ADHD symptoms in students with ADHD
by: fereshteh Amouzadeh, et al.
Published: (2020-11-01)

Donepezil Regulates LPS and Aβ-Stimulated Neuroinflammation through MAPK/NLRP3 Inflammasome/STAT3 Signaling
by: Jieun Kim, et al.
Published: (2021-09-01)

Non-invasive Cognitive Enhancement in Epilepsy
by: Claire S. Jacobs, et al.
Published: (2019-02-01)

Clinical Assessment of Alzheimer’s Disease and Response to Donepezil Treatment
by: Serge Gauthier
Published: (2020-12-01)

The Computer Simulation of Therapy with the NMDA Antagonist in Excitotoxic Neurodegeneration in an Alzheimer’s Disease-like Pathology
by: Dariusz Świetlik, et al.
Published: (2022-03-01)

The Role of NMDA Receptors in Alzheimer’s Disease
by: Jinping Liu, et al.
Published: (2019-02-01)

Efficacy, safety, and tolerability of serotonin-norepinephrine reuptake inhibitors in controlling ADHD symptoms: a systematic review and meta-analysis
by: Ramin Abdi Dezfouli, et al.
Published: (2024-01-01)

Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis
by: Dominik Glinz, et al.
Published: (2019-06-01)

Development of novel salicylic acid–donepezil–rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease
by: Yi Zhou, et al.
Published: (2023-12-01)

Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimer’s Disease, in Silico Trials
by: Dariusz Świetlik, et al.
Published: (2022-04-01)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease
by: Davide V Moretti, et al.
Published: (2014-07-01)

The influence of physical activity on reducing ADHD symptoms – a systematic review
by: Maria Kotulska, et al.
Published: (2023-05-01)